You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯環藥業(600513.SH):子公司擬收購龍一醫藥51%股份
格隆匯 05-28 17:08

格隆匯5月28日丨聯環藥業(600513.SH)公佈,公司為進一步深化西南區域戰略佈局,提升公司在西南區域市場的整體掌控力,鞏固公司在區域內的優勢地位,公司全資子公司聯環投資擬與川通發、陽雨憲、龍小蘭簽訂關於龍一醫藥的《股權轉讓協議》。聯環投資擬以現金方式收購川通發、陽雨憲先生、龍小蘭女士所持有的龍一醫藥51%股份。

公司於2019年完成對位於四川省彭州市的成都亞中生物製藥有限責任公司股權收購項目,本次收購系公司進一步深化西南區域戰略佈局的重要舉措,將對聯環藥業產業拓展和價值提升產生顯著的推動作用。一方面,此次收購有助於實現公司醫藥製造板塊與龍一醫藥流通渠道的深度整合,構建完整的“研發-生產-流通”產業鏈閉環,提升公司在西南區域市場的整體掌控力;另一方面,依託彭州生物醫藥產業集羣優勢,本次收購完成後將有力促進公司在西南地區構建第二戰略支點,打造覆蓋川渝並輻射整個西南地區的醫藥產業樞紐,與長三角總部形成跨區域聯動的雙核發展格局,為構建全國性醫藥產業版圖提供重要支撐。此外,本次收購完成後將大幅提升公司資產規模,為公司的長期穩定發展和股東價值提升奠定堅實基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account